RJA
DFTX

Raymond James & Associates’s Definium Therapeutics DFTX Stock Holding History

Raymond James & Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,206
Closed -$12K – 4068
2022
Q2 		$12K Buy
1,206
+71
+6% +$898 ﹤0.01% 3924
2022
Q1 		$19K Buy
+1,135
New +$19.7K ﹤0.01% 4014

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Raymond James & Associates's DFTX Position: Q3 2022 in Review

Raymond James & Associates sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 1,206 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in DFTX in Q1 2022 and held it in 2 quarters. The position peaked at $19K in Q1 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Raymond James & Associates reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,206 Definium Therapeutics shares in Q3 2022, an estimated $12K.
  • Raymond James & Associates first reported a position in Definium Therapeutics in Q1 2022 and held it in 2 quarters.
  • Raymond James & Associates's Definium Therapeutics position peaked at $19K in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.